drugset
drugset / Trial / NCT07199569

Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells

NCT07199569 ↗

Phase 2 Active not recruiting 970 enrolled Bavarian Nordic ICON plc · collab
RandomizedParallel-groupQuadruple-blindOther

Summary

Randomized, double-blind, phase 2b trial to assess comparability in immunogenicity, safety, and reactogenicity of MVA-BN vaccine manufactured in primary chicken embryo fibroblast (CEF) cells and the CCX.E10 quail cell line in adults

Timeline

Start
2025-10-27
Primary completion
2026-11-30
Completion
2026-11-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator IMVAMUNE Vaccine 5e+07 unknown Subcutaneous
Comparator IMVAMUNE Vaccine 3.95e+08 unknown Subcutaneous

Indications

monkeypox